Annual School of Nursing Oncology

Podsada Discusses Biomarker Testing and ADC Therapies in Breast Cancer

August 16, 2022

The growing availability of biomarkers has led to the advent of more targeted therapies such as the antibody-drug conjugates (ADCs) fam-trastuzumab deruxtecan-nxki, ado-trastuzumab emtansine, and sacituzumab govitecan-hziy.

Stephanie Jackson Unpacks Recent Advances in Leukemia Treatments

August 15, 2022

Stephanie Jackson, DNP, MSN, RN, AOCNP, BMTCN, discusses the trajectory of targeted and CAR T-cell therapies such as ivosidenib and brexucabtagene autoleucel, and what nurses need to know about these treatments to be able to practice at the top of their licensure.

Approaches to Urothelial Care Call for Nuanced AE Management

August 11, 2022

Avelumab, erdafitinib, and enfortumab vedotin-ejfv are 3 critical drugs in the treatment of urothelial cancer with distinct safety profiles, according to a presentation at the 6th Annual School of Nursing Oncology™ Meeting.